Pfizer Valuation
| PFE Stock | USD 26.30 0.19 0.72% |
At this time, the company appears to be undervalued. Pfizer Inc holds a recent Real Value of $27.4 per share. The prevailing price of the company is $26.3. Our model determines the value of Pfizer Inc from analyzing the company fundamentals such as Operating Margin of 0.33 %, shares outstanding of 5.67 B, and Return On Equity of 0.0454 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Pfizer's valuation include:
Price Book 1.6101 | Enterprise Value | Enterprise Value Ebitda 14.8347 | Price Sales 2.5283 | Forward PE 8.9206 |
Undervalued
Today
Please note that Pfizer's price fluctuation is very steady at this time. Calculation of the real value of Pfizer Inc is based on 3 months time horizon. Increasing Pfizer's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pfizer stock is determined by what a typical buyer is willing to pay for full or partial control of Pfizer Inc. Since Pfizer is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pfizer Stock. However, Pfizer's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 26.3 | Real 27.4 | Target 31.78 | Hype 26.28 |
The real value of Pfizer Stock, also known as its intrinsic value, is the underlying worth of Pfizer Inc Company, which is reflected in its stock price. It is based on Pfizer's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Pfizer's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Pfizer Inc helps investors to forecast how Pfizer stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pfizer more accurately as focusing exclusively on Pfizer's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Pfizer's intrinsic value based on its ongoing forecasts of Pfizer's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Pfizer's closest peers. If more than one evaluation category is relevant for Pfizer we suggest using both methods to arrive at a better estimate.
Pfizer Cash |
|
Pfizer Valuation Trend
Comparing Pfizer's enterprise value against its market capitalization is a good way to estimate the value of Pfizer Inc uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Pfizer Total Value Analysis
Pfizer Inc is at this time forecasted to have company total value of 205.25 B with market capitalization of 150.12 B, debt of 75.04 B, and cash on hands of 2.85 B. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Pfizer fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
205.25 B | 150.12 B | 75.04 B | 2.85 B |
Pfizer Investor Information
About 68.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.61. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pfizer Inc has Price/Earnings To Growth (PEG) ratio of 0.2. The entity last dividend was issued on the 24th of January 2025. The firm had 1054:1000 split on the 17th of November 2020. Based on the analysis of Pfizer's profitability, liquidity, and operating efficiency, Pfizer Inc is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.0491 | 0.0517 |
|
| |||||
| Total Cash From Operating Activities | 12.4 B | 10 B |
|
| |||||
| Operating Income | 3.7 B | 3.9 B |
|
|
Pfizer Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pfizer has an asset utilization ratio of 25.83 percent. This indicates that the Company is making $0.26 for each dollar of assets. An increasing asset utilization means that Pfizer Inc is more efficient with each dollar of assets it utilizes for everyday operations.Pfizer Ownership Allocation
Pfizer owns a total of 5.67 Billion outstanding shares. Over half of Pfizer's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that on December 6, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Pfizer Inc's common stock.Pfizer Profitability Analysis
The company reported the last year's revenue of 58.5 B. Total Income to common stockholders was 2.17 B with profit before taxes, overhead, and interest of 41.43 B.Pfizer Past Distributions to stockholders
| 2nd of December 2024 | ||
| 3rd of September 2024 | ||
| 14th of June 2024 | ||
| 1st of March 2024 | ||
| 26th of January 2024 | ||
| 4th of December 2023 | ||
| 5th of September 2023 | ||
| 9th of June 2023 | ||
| 3rd of March 2023 |
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Pfizer's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Pfizer and how it compares across the competition.
About Pfizer Valuation
The stock valuation mechanism determines Pfizer's current worth on a weekly basis. Our valuation model uses a comparative analysis of Pfizer. We calculate exposure to Pfizer's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pfizer's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 33.1 B | 30.4 B | |
| Pretax Profit Margin | 0.02 | 0.02 | |
| Operating Profit Margin | 0.05 | 0.05 | |
| Net Profit Margin | 0.03 | 0.03 | |
| Gross Profit Margin | 0.44 | 0.62 |
A single share of Pfizer represents a small ownership stake in the entity. As a stockholder of Pfizer, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Pfizer Dividends Analysis For Valuation
At present, Pfizer's Dividend Yield is projected to increase slightly based on the last few years of reporting. The current year's Dividend Payout Ratio is expected to grow to 4.12, whereas Dividend Paid And Capex Coverage Ratio is forecasted to decline to 0.57. . At present, Pfizer's Price Earnings Ratio is projected to increase significantly based on the last few years of reporting.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 10.6 B | 11.2 B | |
| Dividend Yield | 0.05 | 0.05 | |
| Dividend Payout Ratio | 3.93 | 4.12 | |
| Dividend Paid And Capex Coverage Ratio | 0.60 | 0.57 |
There are various types of dividends Pfizer can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Pfizer shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Pfizer Inc directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Pfizer pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Pfizer by the value of the dividends paid out.
Pfizer Growth Indicators
Investing in growth stocks can be very risky. If the company such as Pfizer does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 5.7 B | |
| Quarterly Earnings Growth Y O Y | -0.982 | |
| Forward Price Earnings | 8.9206 |
Pfizer Current Valuation Indicators
Valuation refers to the process of determining the present value of Pfizer Inc and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Pfizer we look at many different elements of the entity such as Pfizer's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Pfizer, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Pfizer's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Pfizer's worth.Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |